ena-STUDY-Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea-02-03-2021-16:39:51:902-1439
AZD6738, in combination with durvalumab in advanced gastric cancer
AZD6738 is an orally dosed selective and potent inhibitor of Ataxia Telangiectasis and Rad3 Related (ATR) kinase. We report phase 2 trial , an oral inhibitor of the serine/threonine protein kinase Ataxia Telangiectasia and Rad3 Related (ATR), ceralasertib at 240 mg BD on days 15 to 28 in a 28-day cycle in combination with durvalumab at 1500 mg day 1 every 4 weeks in patients with advanced gastric cancer. Among enrolled 31 patients, 11 stable disease, and 13 disease progression were observed. The ORR was 22.6%, DCR 58.1 %, median PFS 3.0 months (95% confidence interval (CI), 2.1-3.9), and median OS was 6.7 months (95% CI, 3.8-9.6). ATM protein loss or enriched mutation signature of homologous repair deficiency were associated with superior PFS. Most common adverse events were tolerable. Ceralasertib in combination with durvalumab demonstrated promising anti-tumor activity with durable responses in pretreated metastatic gastric cancer patients.
AZD6738 is an orally dosed selective and potent inhibitor of Ataxia Telangiectasis and Rad3 Related (ATR) kinase. We report phase 2 trial , an oral inhibitor of the serine/threonine protein kinase Ataxia Telangiectasia and Rad3 Related (ATR), ceralasertib at 240 mg BD on days 15 to 28 in a 28-day cycle in combination with durvalumab at 1500 mg day 1 every 4 weeks in patients with advanced gastric cancer. Among enrolled 31 patients, 11 stable disease, and 13 disease progression were observed. The ORR was 22.6%, DCR 58.1 %, median PFS 3.0 months (95% confidence interval (CI), 2.1-3.9), and median OS was 6.7 months (95% CI, 3.8-9.6). ATM protein loss or enriched mutation signature of homologous repair deficiency were associated with superior PFS. Most common adverse events were tolerable. Ceralasertib in combination with durvalumab demonstrated promising anti-tumor activity with durable responses in pretreated metastatic gastric cancer patients.